Introduction:
EUROAPI invests US$50 million (€50 million) to establish a new production plant at its Budapest site, Europe.
Features:
The new state-of-the-art manufacturing plant will double Budapest site's prostaglandin production.
The upcoming production plant in Budapest is set to be a pioneering facility equipped with advanced features to promote sustainability and operational efficiency.
The primary objective of this project is to address capacity limitations that the current manufacturing setup might be experiencing.
This project is designed in two phases. The first phase, scheduled from 2023 to 2025 and accounting for approximately two-thirds of the total investment, will concentrate on overcoming existing bottlenecks and enhancing the production capacity.
The second phase, spanning from 2026 to 2027, will focus on the construction and integration of new multi-purpose manufacturing equipment.
The facility is anticipated to play a pivotal role in fulfilling pharmaceutical manufacturing requirements while contributing positively to the environment and potential future developments in the field.
The new manufacturing facility will be operational by 2027.
Specifications:
Name EUROAPI
Type New Construction
Budget US$50 million(€50 million)
Year 2027
